Physician profile
Roberto S Perez
NPI 1700867553
$3,181.64
in general payments reported to CMS, 2019-2025
21 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $613 · 2021: $355 · 2022: $155 · 2023: $154 · 2024: $337 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,470.00 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $480.94 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $354.48 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Merz North America, INC. | $157.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.37 | 2019-2025 | Jardiance |
| Abbott Laboratories | $110.72 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $86.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $84.91 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $75.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.96 | 2019-2020 | |
| Exact Sciences Corporation | $36.38 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $30.32 | 2019-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.43 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.48 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $16.43 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.25 | 2025 | |
| Glaxosmithkline, LLC. | $16.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2020 | |
| Allergan, INC. | $14.60 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.05 | 2020 | |
| Genentech USA, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.